通关藤注射液联合GC方案治疗晚期NSCLC的效果及对外周血T淋巴细胞亚群的影响

Efficacy of Tongguanteng Injection combined with GC regimen in the treatment of advanced NSCLC and its influence on peripheral blood T lymphocyte subsets

目的探讨通关藤注射液联合吉西他滨+顺铂(GC)方案治疗晚期非小细胞肺癌(NSCLC)的效果及对外周血T淋巴细胞亚群的影响。方法选取2020年3月至2021年3月中国中医科学院广安门医院南区肿瘤科收治的晚期NSCLC患者70例,按随机数字表法分成对照组与研究组,每组各35例。对照组行单纯GC方案化疗,研究组行GC方案+通关藤注射液联合治疗。记录两组不良反应,评价近期疗效,观察两组T淋巴细胞亚群、生活质量变化。结果研究组近期疗效优于对照组,且客观缓解率高于对照组,差异有统计学意义(P<0.05)。两组疾病控制率比较,差异无统计学意义(P>0.05)。治疗2周期后,两组CD3^(+)、CD4^(+)占比及CD4^(+)/CD8^(+)均升高,且研究组高于对照组,CD8^(+)占比下降,研究组低于对照组,差异有统计学意义(P<0.05)。治疗两周期后两组机体功能健康状况评分均升高且研究组高于对照组,差异有统计学意义(P<0.05)。与对照组比较,研究组Ⅲ~Ⅳ度恶心呕吐、Ⅲ~Ⅳ度白细胞减少发生率明显下降,而Ⅰ~Ⅱ度白细胞减少发生率升高,差异有统计学意义(P<0.05)。结论通关藤注射液联合GC方案治疗晚期NSCLC可获得更佳的近期疗效,改善T淋巴亚群分布,促进机体免疫功能恢复,并能减轻化疗毒副作用,提升患者生活质量,值得临床借鉴。

Objective To investigate the efficacy of Tongguanteng Injection combined with GC regimen in the treatment of advanced non-small cell lung cancer(NSCLC)and its influence on peripheral blood T lymphocyte subsets.Methods Seventy patients with NSCLC treated in the Department of Oncology,Guang’anmen Hospital Southern District,China Academy of Traditional Chinese Medicine from March 2020 to March 2021 were selected and they were divided into control group and study group according to the random number table method,with 35 patients in each group.The control group was treated with GC alone,and the study group was treated with GC+Tongtengteng Injection.The adverse reactions of the two groups were recorded,the short-term efficacy was evaluated,and the changes of T lymphocyte subsets and quality of life were observed.Results The short-term efficacy of the study group was better than the control group,and the objective remission rate was higher than the control group,the differences were statistically significant(P<0.05).There was no significant difference in disease control rate between the two groups(P>0.05).After two cycles of treatment,the proportion of CD3^(+),CD4^(+)and CD4^(+)/CD8^(+)in both groups increased,and those in the study group were higher than the control group,and the proportion of CD8^(+)was decreased,and the study group was lower than the control group,the differences were statistically significant(P<0.05).After two cycles of treatment,KPS score of both groups increased and the study group was higher than the control group,the differences were statistically significant(P<0.05).Compared with the control group,the incidence of gradeⅢ-Ⅳnausea and vomiting and gradeⅢ-Ⅳleukopenia was significantly decreased in the study group,while the incidence of gradeⅠ-Ⅱleukopenia was increased,and the differences were statistically significant(P<0.05).Conclusion Tongguanteng Injection and combined GC regimen in the treatment of advanced NSCLC can achieve better short-term efficacy,improve the distribution of T lymphatic subgroups,promote the recovery of immune function,reduce the side effects of chemotherapy,and improve the quality of life of patients,which is worthy of clinical reference.